Monitoring vaccine safety during measles mass immunization campaigns: Clinical and programmatic issues

Journal of Infectious Diseases

Volumn 187, Issue SUPPL. 1, 2003, Pages

  Pless, Robert P ^a,c,d   Bentsi Enchill, Adwoa D ^b   Duclos, Philippe ^b  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c HEALTH CANADA   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MORU VIRATEN;

ALLERGY; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; BELL PALSY; BRAIN DISEASE; CONVULSION; DIARRHEA; DRUG SAFETY; EDEMA; ENCEPHALITIS; ENCEPHALOMYELITIS; ERYTHEMA MULTIFORME; FEBRILE CONVULSION; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEALTH PROGRAM; HEALTH SERVICE; HERPES ZOSTER; HUMAN; HYPERVENTILATION; IMMUNIZATION; LEUKOCYTOCLASTIC VASCULITIS; LYMPHADENOPATHY; MEASLES; MEASLES VACCINATION; MENINGITIS; MYELITIS; MYOCARDITIS; NEUROTOXICITY; PAIN; PAROTITIS; PETECHIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; SYNCOPE; THROMBOCYTOPENIA; TUBERCULOSIS; VOMITING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MEASLES; MEASLES VACCINE; SAFETY; WORLD HEALTH ORGANIZATION;

EID: 0038324044     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368049     Document Type: Review

References (30)

1. Riots rock Algerian town after babies die of measles jabs. Tehran Times, 28 December 2001.
2. Foster K. Measles outbreak as MMR fears rise. The Scottsman, 13 March 2002. Available at: http://www.thescotsman.co.uk/index.cfm?id=278802002.
3. Measles returns to Scotland. The Guardian Unlimited, 13 March 2002. Available at: http://www.guardian.co.uk/Archive/Article/0,4273,4373458,00.html.
4. Shin DH. 24 students suffer reaction to measles vaccine. Chosun Ilbo, 8 June 2001. Available at: http://english.chosun.com/w21data/html/news/200106/200106080174.h tml (search for "measles"; scroll to article).
5. World Health Organization. Safety of mass immunization campaigns: aide-memoire to ensure safety during mass immunization campaigns with injectable vaccines, 2002. Available at: http://www.who.int/vaccines-surveillance/ISPP/MainResources.shtml . Accessed 31 August 2002.
6. World Health Organization. Mass measles campaigns: reporting and investigating adverse events following immunization, 2002. Available at: http://www.who.int/vaccines-surveillance/ISPP/AEFI_Measles_EnRvsd 3.doc. Accessed 30 August 2002.
7. World Health Organization. Supplementary information on vaccine safety. Part 1. Field issues. Geneva: WHO 2000 (WHO/V&B/00.24).
8. World Health Organization. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization. Geneva: WHO 2000 (WHO/V&B/00.36).
9. Mehta U, Milstien JB, Duclos P, Folb PI. Developing a national system for dealing with adverse events following immunization. Bull World Health Organ 2000; 78:170-7.
10. World Health Organization. Surveillance of adverse events following immunization - field guide for managers of immunization programmes. Geneva: WHO, 1993 (WHO/EPI/TRAM/93.02 REV. 1).
11. World Health Organization Regional Office of the Western Pacific. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila: WHO, 1999 (WPRO/EPI/99.01).
12. National Measles and Rubella Campaign. Commun Dis Rep CDR Wkly 1994;4:147, 150.
13. Committee on Safety of Medicines. Adverse reactions to measles-rubella vaccine. Curr Prob Pharmacovigilance 1995; 21:9-10. Available at: http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm
14. Division of Immunization, Health Canada. Canadian national report on immunization, 1996. Can Commun Dis Rep 1997; 23(S4).
15. Sciberras J. Adverse vaccine events reported during the Ontario measles immunization campaign. Public Health Epidemiol Rep Ontario 1996; 7:7-12.
16. Daly P, Pielak K. The 1996 measles elimination campaign in British Columbia. Measles Update 1997;5. Available at: http://www.hc-sc.gc.ca/hpb/lcdc/publicat/measles/mesl5-2.html. Accessed 30 May 2002.
17. D'Souza RM, Campbell-Lloyd S, Isaacs D, et al. Adverse events following immunization associated with the 1998 Australian measles control campaign. Commun Dis Intell 2000; 24:27-33.
18. Burgess MA, Heath TC, McIntyre PB. The measles control campaign and immunization adverse events. Commun Dis Intell 1998; 22:136-8.
19. Yang BG. Analysis of the adverse events after measles mass catch-up campaign in the Republic of Korea, 2001. In: Program and abstracts of the conference on the First Year Evaluation of the 5 Year Measles Elimination Program in Korea, and Challenges and Opportunities to Eliminate Measles in the Western Pacific Region (Seoul), 2001.
20. Nationwide campaign for vaccination of adults against rubella and measles - Costa Rica, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:976-9.
21. Ion-Nedelcu N, Craciun D, Pitigoi D, et al. Measles elimination: a mass immunization campaign in Romania. Am J Public Health 2001; 91:1042-5.
22. Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saf 1998; 19:435-54.
23. Souza da Cunhaa S, Rodrigues LC, Barreto ML, Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 2002; 20:1106-12.
24. Stratton KR, Howe CJ, Johnston RB, eds. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academy Press, 1994.
25. Howson CP, Howe CJ, Fineberg HV, eds. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academy Press, 1991.
26. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995;85:1706-9.
27. Clements CJ. MMR vaccine and its public image. WHO Pharmaceuticals Newslett 2001; 1:15-7. Available at: http://www.who.int/medicines/library/pnewslet/npn0101.html
28. Cutts F, Henao-Restrepo AM, Olive JM. Measles elimination: progress and challenges. Vaccine 1999; 17:S47-52.
29. Ivinson AJ. Concern, but not with surveillance. Bull World Health Organ 2000; 78:222-3.
30. World Health Organization. Global training network on vaccine quality (GTN): course on adverse events following immunization (AEFI). Available at: http://www.who.int/vaccines-access/vaccines/Vaccine_Quality/gtn/a efi.htm. Accessed 27 May 2002.